

Manage Your Program:

LVD2016

Sh  
der  
017 : / Jones  
Sign out]  
1:14 AM

Reports List » Response Report

## Global Academy - LVD2016 - Demographic Survey

Likert Avg.  
**N/A**

Total Completed: 234

Options: Show Extended View

**Question 1.**

What is your professional degree?

Response	Count	Graph	Percent †
Physician	145		62%
Nurse Practitioner	47		20%
Physician Assistant	28		12%
Nurse	6		3%
Pharmacist	8		3%
Other (View Responses)	0		0%
<b>Total Responses:</b>	<b>234</b>		

[Respondent Details](#) [Trend Analysis](#)

**Question 2.**

What is your area of practice?

Response	Count	Graph	Percent †
Dermatology	125		53%
Internal Medicine	12		5%
Family Practice/General Practice	65		27%
Other (View Responses)	35		15%
<b>Total Responses:</b>	<b>237</b>		

[Respondent Details](#) [Trend Analysis](#)

**Question 3.**

What is your area of practice?

Response	Count	Graph	Percent †
Solo Private Practice	60		26%
Group Private Practice	88		38%
Veterans Administration	4		2%

Response	Count	Graph	Percent
Indian Health Services	1		< 1%
Community/County Health Services	17		7%
Academic Medical Center	16		7%
Hospital-based Practice	29		12%
HMO	19		8%
<b>Total Responses:</b>	<b>234</b>		

[Respondent Details](#) [Trend Analysis](#)

**Question 4.**

How many years have you been practicing medicine since completing residency or qualifying for practice?

Response	Count	Graph	Percent †
<5	59		25%
6-10	41		18%
11-15	35		15%
16-20	29		12%
21-30	43		18%
>31	27		12%
<b>Total Responses:</b>	<b>234</b>		

[Respondent Details](#) [Trend Analysis](#)

**Question 5.**

On average, how many patients do you see in a given week?

Response	Count	Graph	Percent †
<25	14		6%
25-50	27		12%
51-75	42		18%
76-100	62		26%
>100	86		37%
I'm retired	3		1%
<b>Total Responses:</b>	<b>234</b>		

[Respondent Details](#) [Trend Analysis](#)

**Question 6.**

Which are the diseases or disorders that you see most frequently in your daily practice?

Response	Count	Graph	Percent †
Open-ended Text Responses <a href="#">(View Responses)</a>	152		100%

<b>Non-Responders:</b>	82
------------------------	----

**Legend****percent question responses**Proportion of a specific response ( $Qa$ ) to the sum of all responses provided for that question ( $Qt$ ). $percent\ of\ total\ question\ responses = Qa / Qt$ 

(Example: X% of all responses to question Y were "A".)

† Percentages are calculated in three different ways. Click on the "Show Extended View" option at the top of the report to display the additional calculations. In cases where a question is required and only one response is allowed, all three percentages will be equal. The difference between the three calculations is most notable in a choose-all-that-apply question type that is optional.

Reports List » Response Report

## Global Academy - LVD2016 - Objectives Evaluation

Likert Avg.  
**4.29**

Total Completed: 232

Options: Show Extended View

### Question 1.

Strongly Having completed this conference, you are better able to:

Integrate into daily practice evidence-based recommendations on new and emerging therapies for common and uncommon dermatologic diseases.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.358		± 0.861
Response	Count	Graph	Percent †
1=Strongly Disagree	6		3%
2	1		< 1%
3	20		9%
4	82		35%
5=Strongly Agree	123		53%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

Assess the risks and benefits of currently available options for acne.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.375		± 0.869
Response	Count	Graph	Percent †
1=Strongly Disagree	6		3%
2	1		< 1%
3	21		9%
4	76		33%
5=Strongly Agree	128		55%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

Develop optimal treatment strategies for acne that include patient counseling to set expectations and to improve adherence.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.379		± 0.823
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	2		< 1%
3	15		6%
4	88		38%
5=Strongly Agree	122		53%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

Recognize early signs and symptoms of actinic keratoses and squamous cell carcinomas, and other nonmelanoma skin cancers.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.254		± 0.897
Response	Count	Graph	Percent †
1=Strongly Disagree	6		3%
2	3		1%
3	26		11%
4	88		38%
5=Strongly Agree	109		47%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

Design management strategies for actinic keratoses and squamous cell carcinomas that include a plan for sun protection and aggressive follow-up care.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.276		± 0.884
Response	Count	Graph	Percent †

1=Strongly Disagree	6		3%
2	1		< 1%
3	28		12%
4	85		37%
5=Strongly Agree	112		48%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

Describe the intrinsic and extrinsic factors that contribute to underlying changes in facial anatomy.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.164		± 0.966
Response	Count	Graph	Percent †
1=Strongly Disagree	9		4%
2	2		< 1%
3	32		14%
4	88		38%
5=Strongly Agree	101		44%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

Identify the appropriate fillers and/or toxins to use for various areas of the face.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.091		± 0.969
Response	Count	Graph	Percent †
1=Strongly Disagree	9		4%
2	3		1%
3	36		16%
4	94		41%
5=Strongly Agree	90		39%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

Compare and contrast the benefits and limitations of newer surgical and nonsurgical techniques and topical treatment options for aesthetic and procedural dermatology.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.112		± 0.974
Response	Count	Graph	Percent †
1=Strongly Disagree	9		4%
2	3		1%
3	35		15%
4	91		39%
5=Strongly Agree	94		41%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

Discuss the most current evidence-based guidelines for differential diagnosis and assessment of atopic dermatitis.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.297		± 0.864
Response	Count	Graph	Percent †
1=Strongly Disagree	7		3%
2	2		< 1%
3	14		6%
4	101		44%
5=Strongly Agree	108		47%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

Develop a strategy for the optimal management of atopic dermatitis, including rotational regimens.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.263		± 0.875
Response	Count	Graph	Percent †
1=Strongly Disagree	6		3%
2	3		1%
3	21		9%

4	96		41%
5=Strongly Agree	106		46%
<b>Total Responses:</b>	<b>232</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>

Recognize the clinical and laboratory tests available for detecting and evaluating onychomycosis.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.328		± 0.885
Response	Count	Graph	Percent †
1=Strongly Disagree	7		3%
2	2		< 1%
3	17		7%
4	88		38%
5=Strongly Agree	118		51%
<b>Total Responses:</b>	<b>232</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>

Evaluate the results of clinical studies on new and emerging treatments for onychomycosis.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.375		± 0.838
Response	Count	Graph	Percent †
1=Strongly Disagree	6		3%
2	1		< 1%
3	15		6%
4	88		38%
5=Strongly Agree	122		53%
<b>Total Responses:</b>	<b>232</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>

Interpret and evaluate emerging clinical trial data related to the mechanisms of action, efficacy, and safety of currently available and emerging biologics and other agents used to treat psoriasis.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.



Response	Count	Graph	Percent †
All Respondents	4.306		± 0.876
1=Strongly Disagree	7		3%
2	0		0%
3	22		9%
4	89		38%
5=Strongly Agree	114		49%
<b>Total Responses:</b>	<b>232</b>	Respondent Details Trend Analysis	

Formulate a management plan, based on existing guidelines and emerging evidence, that incorporates updated recommendations for patients with psoriasis using topical and/or systemic therapies.  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.319		± 0.884
Response	Count	Graph	Percent †
1=Strongly Disagree	7		3%
2	0		0%
3	23		10%
4	84		36%
5=Strongly Agree	118		51%
<b>Total Responses:</b>	<b>232</b>	Respondent Details Trend Analysis	

Assess and manage comorbidities in patients with psoriasis.  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.345		± 0.864
Response	Count	Graph	Percent †
1=Strongly Disagree	7		3%
2	0		0%
3	18		8%
4	88		38%
5=Strongly Agree	119		51%
<b>Total Responses:</b>	<b>232</b>	Respondent Details Trend Analysis	

Recognize dermatologic conditions that should be considered in differential diagnosis of a patient with signs and symptoms of rosacea.  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.272		± 0.882
Response	Count	Graph	Percent †
1=Strongly Disagree	7		3%
2	1		< 1%
3	22		9%
4	94		41%
5=Strongly Agree	108		47%
<b>Total Responses:</b>	<b>232</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>

Identify agents approved for use in treating rosacea.  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.310		± 0.872
Response	Count	Graph	Percent †
1=Strongly Disagree	7		3%
2	1		< 1%
3	18		8%
4	93		40%
5=Strongly Agree	113		49%
<b>Total Responses:</b>	<b>232</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>

Describe factors, including vehicle formulation, that may affect the efficacy and tolerability of, and patient satisfaction with, agents used in management of rosacea.  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.315		± 0.873
Response	Count	Graph	Percent †
1=Strongly Disagree	7		3%

2	1		< 1%
3	18		8%
4	92		40%
5=Strongly Agree	114		49%
<b>Total Responses:</b>	<b>232</b>		

[Respondent Details](#) [Trend Analysis](#)

Diagnose and manage dermatologic symptoms resulting from infectious disease.  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.280		± 0.904
Response	Count	Graph	Percent †
1=Strongly Disagree	8		3%
2	0		0%
3	23		10%
4	89		38%
5=Strongly Agree	112		48%
<b>Total Responses:</b>	<b>232</b>		

[Respondent Details](#) [Trend Analysis](#)

**Legend**

**percent question responses**  
 Proportion of a specific response (Qa) to the sum of all responses provided for that question (Qt).  
 $percent\ of\ total\ question\ responses = Qa / Qt$   
 (Example: X% of all responses to question Y were "A".)

† Percentages are calculated in three different ways. Click on the "Show Extended View" option at the top of the report to display the additional calculations. In cases where a question is required and only one response is allowed, all three percentages will be equal. The difference between the three calculations is most notable in a choose-all-that-apply question type that is optional.

Reports List » Response Report

**Global Academy - LVD2016 - Speaker Evaluation**

Likert Avg.  
**4.52**

Total Completed: 232

Options: Show Extended View

**Question 1.**

THURSDAY, NOVEMBER 10

**New Antifungals in Onychomycosis and Tinea • Theodore Rosen, MD**

Dr. Rosen was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.636		± 0.762
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%
3	6		3%
4	47		21%
5=Strongly Agree	166		74%
<b>Total Responses:</b>	<b>225</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	7		

**Rosacea: What's New in Pathophysiology and Treatment • Hilary E. Baldwin, MD; Linda F. Stein Gold, MD**

Dr. Baldwin was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.360		± 1.050
Response	Count	Graph	Percent †
1=Strongly Disagree	12		6%

2	0		0%
3	16		8%
4	50		25%
5=Strongly Agree	125		62%
<b>Total Responses:</b>	<b>203</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	29		

Dr. Stein Gold was an effective presenter  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.600		± 0.785
Response	Count	Graph	Percent †
1=Strongly Disagree	6		3%
2	0		0%
3	6		3%
4	54		24%
5=Strongly Agree	159		71%
<b>Total Responses:</b>	<b>225</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	7		

**New Developments in Atopic Dermatitis · Jonathan I. Silverberg, MD, PhD, MPH**

Dr. Silverberg was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.531		± 0.815
Response	Count	Graph	Percent †
1=Strongly Disagree	6		3%
2	2		< 1%
3	5		2%
4	67		29%
5=Strongly Agree	148		65%

<b>Total Responses:</b>	<b>228</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>
<i>Non-Responders:</i>	4	

**Panel Discussion (Drs. Baldwin, Rosen, Silverberg, Stein Gold)**

Panelists were effective presenters

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.564		± 0.792
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%
3	10		4%
4	56		25%
5=Strongly Agree	155		68%
<b>Total Responses:</b>	<b>227</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	5		

**Actinic Keratosis and Other NMSC · Brian Berman, MD, PhD**

Dr. Berman was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.520		± 0.803
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%
3	12		5%
4	63		28%
5=Strongly Agree	148		65%
<b>Total Responses:</b>	<b>229</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	3		

## Update on Contact Dermatitis: Basics and More · Jonathan I. Silverberg, MD, PhD, MPH

Dr. Silverberg was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.585		± 0.782
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%
3	9		4%
4	54		24%
5=Strongly Agree	160		70%
<b>Total Responses:</b>	<b>229</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	3		

## Panel Discussion (Drs. Berman, Silverberg)

Panelists were effective presenters







(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.547		± 0.786
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%
3	8		4%
4	62		28%
5=Strongly Agree	147		66%
<b>Total Responses:</b>	<b>223</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	9		

**Acne: Topical & Future Treatments Systemic & Hormonal Treatments • Hilary E. Baldwin, MD; Linda F. Stein Gold, MD**







Dr. Baldwin was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.371		± 1.000
Response	Count	Graph	Percent †
1=Strongly Disagree	10		5%
2	0		0%
3	17		8%
4	53		26%
5=Strongly Agree	122		60%
<b>Total Responses:</b>	<b>202</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	30		

Dr. Stein Gold was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.548		± 0.775
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	0		0%
3	10		4%
4	63		28%
5=Strongly Agree	150		66%
<b>Total Responses:</b>	<b>228</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	4		

**Control of Excessive Scarring • Brian Berman, MD, PhD**

Dr. Berman was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)



Sample	Mean	Graph	Std. Dev.
All Respondents	4.500		± 0.794
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	0		0%
3	13		6%
4	68		30%
5=Strongly Agree	142		62%
<b>Total Responses:</b>	<b>228</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	4		

**Infectious Diseases in Dermatology • Theodore Rosen, MD**

Dr. Rosen was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.633		± 0.741
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	0		0%
3	6		3%
4	52		23%
5=Strongly Agree	166		72%
<b>Total Responses:</b>	<b>229</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	3		

**Panel Discussion (Drs. Baldwin, Berman, Rosen, Stein Gold)**

Panelists were effective presenters

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.558		± 0.771

Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	0		0%
3	9		4%
4	62		27%
5=Strongly Agree	150		66%
<b>Total Responses:</b>	<b>226</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	6		

### Great Cases from the Las Vegas Dermatology Society

Dr. Bellew was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.482		± 0.804
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	2		< 1%
3	13		6%
4	65		30%
5=Strongly Agree	134		61%
<b>Total Responses:</b>	<b>218</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	14		

Dr. Bettencourt was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.475		± 0.804
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%
3	11		5%
4	72		32%

5=Strongly Agree	134		60%
<b>Total Responses:</b>	<b>223</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	9		

Ms. Call was an effective presenter  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.461		± 0.820
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%
3	13		6%
4	69		32%
5=Strongly Agree	131		60%
<b>Total Responses:</b>	<b>219</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	13		

Dr. Greenberg was an effective presenter  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.464		± 0.822
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%
3	14		6%
4	68		31%
5=Strongly Agree	134		60%
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Dr. Mobini was an effective presenter  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.482		± 0.787
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	1		< 1%
3	13		6%
4	68		31%
5=Strongly Agree	132		61%
<b>Total Responses:</b>	<b>218</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	14		

**Question 2.**  
FRIDAY, NOVEMBER 11

**Translating the Science of Psoriasis • Kenneth B. Gordon, MD**

Dr. Gordon was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.533		± 0.762
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	0		0%
3	7		3%
4	71		32%
5=Strongly Agree	142		63%
<b>Total Responses:</b>	<b>225</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	7		

**Co-morbidities and Psoriasis • Joel M. Gelfand, MD, MSCE**

Dr. Gelfand was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
--------	------	-------	-----------

All Respondents	4.547		± 0.818
<b>Response</b>	<b>Count</b>	<b>Graph</b>	<b>Percent †</b>
1=Strongly Disagree	5		2%
2	2		< 1%
3	11		5%
4	54		24%
5=Strongly Agree	153		68%
<b>Total Responses:</b>	<b>225</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	7		

**Principals of Topical Therapy for Psoriasis: Today and Tomorrow • Linda F. Stein Gold, MD**

Dr. Stein Gold was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

<b>Sample</b>	<b>Mean</b>	<b>Graph</b>	<b>Std. Dev.</b>
All Respondents	4.573		± 0.765
<b>Response</b>	<b>Count</b>	<b>Graph</b>	<b>Percent †</b>
1=Strongly Disagree	5		2%
2	0		0%
3	8		4%
4	60		27%
5=Strongly Agree	152		68%
<b>Total Responses:</b>	<b>225</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	7		

**Phototherapy for Psoriasis • Kenneth B. Gordon, MD**

Dr. Gordon was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

<b>Sample</b>	<b>Mean</b>	<b>Graph</b>	<b>Std. Dev.</b>
All Respondents	4.513		± 0.773
<b>Response</b>	<b>Count</b>	<b>Graph</b>	<b>Percent †</b>

1=Strongly Disagree	5		2%
2	0		0%
3	9		4%
4	72		32%
5=Strongly Agree	140		62%
<b>Total Responses:</b>	<b>226</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	6		

**Practical Use and Management of Methotrexate and Cyclosporine • Bruce E. Strober, MD, PhD**

Dr. Strober was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.542		± 0.784
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	0		0%
3	11		5%
4	61		27%
5=Strongly Agree	148		66%
<b>Total Responses:</b>	<b>225</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	7		

**Small Molecules for the Systemic Treatment of Psoriasis • Craig L. Leonardi, MD**

Dr. Leonardi was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.547		± 0.781
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	0		0%

3	10		4%
4	61		27%
5=Strongly Agree	147		66%
<b>Total Responses:</b>	<b>223</b>	<a href="#">Respondent Details</a>	<a href="#">Trend Analysis</a>
<i>Non-Responders:</i>	9		

**Panel Discussion (Drs. Gelfand, Gordon, Leonardi, Stein Gold, Strober)**

Panelists were effective presenters

(1=Strongly Disagree,5=Strongly Agree)


Sample	Mean	Graph	Std. Dev.
All Respondents	4.574		± 0.767
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	0		0%
3	8		4%
4	59		26%
5=Strongly Agree	151		68%
<b>Total Responses:</b>	<b>223</b>	<a href="#">Respondent Details</a>	<a href="#">Trend Analysis</a>
<i>Non-Responders:</i>	9		

**Managing Your Patient Using IL-17 Inhibitors: What You Need to Know • Craig L. Leonardi, MD**

Dr. Leonardi was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)







Sample	Mean	Graph	Std. Dev.
All Respondents	4.533		± 0.796
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%
3	10		4%
4	62		28%

5=Strongly Agree	147		65%
<b>Total Responses:</b>	<b>225</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	7		

**TNF Inhibitors: Update for 2016 • Francisco A. Kerdel, BSc, MBBS**

Dr. Kerdel was an effective presenter







(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.484		± 0.808
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%
3	12		5%
4	69		31%
5=Strongly Agree	138		61%
<b>Total Responses:</b>	<b>225</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	7		

**IL 23: Novel Pathways • Bruce E. Strober, MD, PhD**

Dr. Strober was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.540		± 0.786
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%
3	8		4%
4	64		29%
5=Strongly Agree	146		65%
<b>Total Responses:</b>	<b>224</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	8		



### Panel Discussion (Drs. Kerdel, Leonardi, Strober)

Panelists were effective presenters

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.520		± 0.782
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	0		0%
3	10		4%
4	67		30%
5=Strongly Agree	141		63%
<b>Total Responses:</b>	<b>223</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	9		

### Monitoring Patients with Psoriasis on Biologics · Bruce E. Strober, MD, PhD

Dr. Strober was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.570		± 0.767
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	0		0%
3	8		4%
4	60		27%
5=Strongly Agree	150		67%
<b>Total Responses:</b>	<b>223</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	9		

**Quality of Life: Managing Psoriasis · Joel M. Gelfand, MD, MSCE**

Dr. Gelfand was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.522		± 0.814
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%
3	13		6%
4	58		26%
5=Strongly Agree	147		66%
<b>Total Responses:</b>	<b>224</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	8		

**Biosimilars: What's on the Horizon · Bruce E. Strober, MD, PhD**

Dr. Strober was an effective presenter

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.561		± 0.785
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%
3	8		4%
4	59		26%
5=Strongly Agree	150		67%
<b>Total Responses:</b>	<b>223</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	9		

**Panel Discussion (Drs. Gelfand, Strober)**

Panelists were effective presenters

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.541		± 0.776
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	0		0%
3	9		4%
4	64		29%
5=Strongly Agree	144		65%
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	<i>10</i>		

### Perception and Reality – Clinical Cases – Test Yourself Challenge

Panelists were effective presenters

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.518		± 0.763
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	0		0%
3	12		6%
4	65		30%
5=Strongly Agree	137		63%
<b>Total Responses:</b>	<b>218</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	<i>14</i>		

### Question 3.

SATURDAY, NOVEMBER 12

### Have We Forgotten the Curette? • Howard K. Steinman, MD

Dr. Steinman was an effective presenter

(1=Strongly Disagree, 5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.512		± 0.830
Response	Count	Graph	Percent †
1=Strongly Disagree	6		3%
2	0		0%
3	10		5%
4	59		28%
5=Strongly Agree	136		64%
<b>Total Responses:</b>	<b>211</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	21		

### The Aging Process • Burt Steffes, MD

Dr. Steffes was an effective presenter

(1=Strongly Disagree, 5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.512		± 0.807
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%
3	9		4%
4	62		29%
5=Strongly Agree	134		64%
<b>Total Responses:</b>	<b>211</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	21		

### Facial Rejuvenation: What Are the Options? • Christopher B. Zachary, MBBS, FRCP

Dr. Zachary was an effective presenter

(1=Strongly Disagree, 5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.517		± 0.830
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%
3	13		6%
4	53		25%
5=Strongly Agree	139		66%
<b>Total Responses:</b>	<b>211</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	21		

**Panel Discussion (Drs. Steffes, Steinman, Zachary)**

Panelists were effective presenters

(1=Strongly Disagree, 5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.498		± 0.815
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%
3	10		5%
4	62		30%
5=Strongly Agree	131		63%
<b>Total Responses:</b>	<b>209</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	23		

**Facial Shaping: Toxins • Burt Steffes, MD**

Dr. Steffes was an effective presenter

(1=Strongly Disagree, 5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.519		± 0.825

Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%
3	11		5%
4	54		26%
5=Strongly Agree	135		66%
<b>Total Responses:</b>	<b>206</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	26		

**Facial Shaping: Fillers • Burt Steffes, MD**

Dr. Steffes was an effective presenter

(1=Strongly Disagree, 5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.493		± 0.820
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	0		0%
3	13		6%
4	58		28%
5=Strongly Agree	129		63%
<b>Total Responses:</b>	<b>205</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	27		

**Body Contouring: What's Real? What's Not! • Christopher B. Zachary, MBBS, FRCP**

Dr. Zachary was an effective presenter

(1=Strongly Disagree, 5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.495		± 0.816
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%

3	10		5%
4	62		30%
5=Strongly Agree	130		63%
<b>Total Responses:</b>	<b>208</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	24		

### Managing Patient Expectations • Howard K. Steinman, MD

Dr. Steinman was an effective presenter

(1=Strongly Disagree, 5=Strongly Agree)



Sample	Mean	Graph	Std. Dev.
All Respondents	4.512		± 0.814
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	0		0%
3	12		6%
4	56		27%
5=Strongly Agree	132		64%
<b>Total Responses:</b>	<b>205</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	27		

### Panel Discussion (Drs. Steffes, Steinman, Zachary)

Panelists were effective presenters

(1=Strongly Disagree, 5=Strongly Agree)



Sample	Mean	Graph	Std. Dev.
All Respondents	4.500		± 0.815
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	0		0%
3	12		6%

4	58		28%
5=Strongly Agree	129		63%
<b>Total Responses:</b>	<b>204</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	28		

**Question 4.**



**Pharmacists please record your attendance at the conference by answering the following 3 questions:**

**ONLY Pharmacists Must Answer (CPE Monitor):** Did you attend all Thursday (Nov 10) didactic presentations (7.00 Contact Hours)?

Response	Count	Graph	Percent †
Yes	14		93%
No	1		7%
<b>Total Responses:</b>	<b>15</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	217		



**Question 5.**

**ONLY Pharmacists Must Answer (CPE Monitor):** Did you attend all Friday (Nov 10) didactic presentations (6.25 Contact Hours)?

Response	Count	Graph	Percent †
Yes	11		92%
No	1		8%
<b>Total Responses:</b>	<b>12</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	220		

**Question 6.**

**ONLY Pharmacists Must Answer (CPE Monitor):** Did you attend all Saturday (Nov 10) didactic presentations (3.50 Contact Hours)?

Response	Count	Graph	Percent †
Yes	5		42%
No	7		58%
<b>Total Responses:</b>	<b>12</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	220		



**Legend****percent question responses**

Proportion of a specific response ( $Qa$ ) to the sum of all responses provided for that question ( $Qt$ ).

*percent of total question responses =  $Qa / Qt$*

(Example: X% of all responses to question Y were "A".)

† Percentages are calculated in three different ways. Click on the "Show Extended View" option at the top of the report to display the additional calculations. In cases where a question is required and only one response is allowed, all three percentages will be equal. The difference between the three calculations is most notable in a choose-all-that-apply question type that is optional.

Manage Your Program:

LVD2016

Sh  
der, y  
017 : / Jones  
Sign out]  
2:56 AM

Reports List » Response Report

## Global Academy - July 2016 Revised Shared Rutgers Activity Evaluation







Likert Avg.  
**4.37**

Total Completed: 232

Options: Show Extended View

**Question 1.**


Based on the content of the activity, what will you do differently in the care of your patients and/or regarding your professional responsibilities? (Select one)

Response	Count	Graph	Percent †
Implement a change in my practice/workplace.	79		34%
Seek additional information on this topic.	51		22%
Implement a change in my practice/workplace and seek additional information on this topic.	51		22%
Do nothing differently. Current practice/job responsibilities reflect activity recommendations.	45		19%
Do nothing differently. Content was not convincing.	2		< 1%
Do nothing differently. System barriers prevent me from changing my practice/workplace.	4		2%
<b>Total Responses:</b>	<b>232</b>		

Respondent Details Trend Analysis




**Question 2.**

If you anticipate changing one or more aspects of your practice and/or professional responsibilities as a result of your participation in this activity, please briefly describe how you plan to do so.

Response	Count	Graph	Percent †
Open-ended Text Responses (View Responses)	90		100%
<i>Non-Responders:</i>	<i>142</i>		

**Question 3.**



If you plan to change your practice/professional responsibilities, may we contact you in 2 months to see how you are progressing?

Response	Count	Graph	Percent †
Yes	52		22%
No	112		48%
I don't plan to make a change	68		29%
<b>Total Responses:</b>	<b>232</b>		

Respondent Details Trend Analysis


**Question 4.**

Were the patient recommendations based on acceptable practices in medicine?

Response	Count	Graph	Percent †
Yes	227		98%
No	5		2%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	



**Question 5.**

If no, please explain which recommendation(s) were not based on acceptable practices in medicine.

Response	Count	Graph	Percent †
Open-ended Text Responses (View Responses)	8		100%
<i>Non-Responders:</i>	224		


**Question 6.**

Do you think the presentations were without commercial bias and influence?

Response	Count	Graph	Percent †
Yes	222		96%
No	10		4%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

**Question 7.**


If no, please list the presentation(s) that were biased.

Response	Count	Graph	Percent †
Open-ended Text Responses (View Responses)	11		100%
<i>Non-Responders:</i>	221		

**Question 8.**

The presentations met my educational needs by:

This education increased my understanding of the subject.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.556		± 0.694

Response	Count	Graph	Percent †
1=Strongly Disagree	3		1%
2	1		< 1%
3	6		3%
4	76		33%
5=Strongly Agree	146		63%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	







This education will influence how I do my job.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.341		± 0.822
Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	5		2%
3	25		11%
4	80		34%
5=Strongly Agree	120		52%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	







This education will help me improve my job performance.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.323		± 0.829
Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	5		2%
3	27		12%
4	80		34%
5=Strongly Agree	118		51%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	





This education will help me collaborate with other healthcare professionals.  
 (1=Strongly Disagree,5=Strongly Agree)



Sample	Mean	Graph	Std. Dev.
All Respondents	4.341		± 0.833
Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	4		2%
3	30		13%
4	73		31%
5=Strongly Agree	123		53%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a>	<a href="#">Trend Analysis</a>

This education addressed issues in cultural competency.  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.125		± 0.938
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	3		1%
3	50		22%
4	74		32%
5=Strongly Agree	100		43%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a>	<a href="#">Trend Analysis</a>







This education was educationally sound and scientifically balanced.  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.500		± 0.756
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	1		< 1%
3	10		4%

4	77		33%
5=Strongly Agree	140		60%
<b>Total Responses:</b>	<b>232</b>		







[Respondent Details](#) [Trend Analysis](#)

This education was free of commercial bias or influence  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.435		± 0.798
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	1		< 1%
3	12		5%
4	84		36%
5=Strongly Agree	130		56%
<b>Total Responses:</b>	<b>232</b>		

[Respondent Details](#) [Trend Analysis](#)

This education met my expectations.  
(1=Strongly Disagree,5=Strongly Agree)







Sample	Mean	Graph	Std. Dev.
All Respondents	4.483		± 0.756
Response	Count	Graph	Percent †
1=Strongly Disagree	3		1%
2	2		< 1%
3	13		6%
4	76		33%
5=Strongly Agree	138		59%
<b>Total Responses:</b>	<b>232</b>		

[Respondent Details](#) [Trend Analysis](#)

**Question 9.**







This activity should improve my:

Medical or Practice Knowledge  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.496		± 0.727
Response	Count	Graph	Percent †
1=Strongly Disagree	3		1%
2	1		< 1%
3	11		5%
4	80		34%
5=Strongly Agree	137		59%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	







Care Attitudes

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.224		± 0.874
Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	8		3%
3	32		14%
4	84		36%
5=Strongly Agree	106		46%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

Procedural or Cognitive Skills

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.289		± 0.877
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	3		1%
3	26		11%
4	84		36%
5=Strongly Agree	114		49%

<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>
-------------------------	------------	---

**Practice Behavior**  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.259		± 0.854
Response	Count	Graph	Percent †
1=Strongly Disagree	3		1%
2	5		2%
3	29		13%
4	87		38%
5=Strongly Agree	108		47%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

**Patients' Clinical Outcomes**  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.332		± 0.841
Response	Count	Graph	Percent †
1=Strongly Disagree	3		1%
2	5		2%
3	23		10%
4	82		35%
5=Strongly Agree	119		51%
<b>Total Responses:</b>	<b>232</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

**Question 10.**

Please indicate any primary barriers to implementing information acquired at the event to updating and/or redefining your patient care approach? (choose all that apply)

Response	Count	Graph	Percent †
Diagnostic tool/treatment limitation.	59		17%
Diagnostic tool/treatment unavailability.	64		19%
Patients decline diagnostic or treatment intervention.	40		12%



I don't feel confident in implementing this change.	7		2%
Lack of patient education.	29		9%
My practice doesn't permit this type of change.	30		9%
Lack of time to implement	32		9%
I need more education about this topic.	43		13%
Other (View Responses)	34		10%
<b>Total Responses:</b>	<b>338</b>		

[Respondent Details](#) [Trend Analysis](#)

**Question 11.**

How do you think these barriers could be eliminated?

Response	Count	Graph	Percent †
Open-ended Text Responses (View Responses)	232		100%

**Question 12.**

Please rate on a scale of 1 to 5.

(1=Poor, 2=Fair, 3=Average, 4=Good, 5=Excellent)

How would you rate this activity?  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.513		± 0.690
Response	Count	Graph	Percent †
1=Poor	2		< 1%
2	1		< 1%
3	11		5%
4	80		34%
5=Excellent	138		59%
<b>Total Responses:</b>	<b>232</b>		

[Respondent Details](#) [Trend Analysis](#)

**Question 13.**


What issues are you experiencing in your practice/regarding your professional responsibilities that could be addressed in future programming?

Response	Count	Graph	Percent †
Open-ended Text Responses (View Responses)	61		100%

<i>Non-Responders:</i>	171
------------------------	-----

**Question 14.**

Please provide us with any additional comments you would like to make including suggestions for improvement. We welcome your feedback.

Response	Count	Graph	Percent †
Open-ended Text Responses (View Responses)	59		100%
<i>Non-Responders:</i>	173		

**Legend****percent question responses**

Proportion of a specific response ( $Qa$ ) to the sum of all responses provided for that question ( $Qt$ ).

$percent\ of\ total\ question\ responses = Qa / Qt$

(Example: X% of all responses to question Y were "A".)

† Percentages are calculated in three different ways. Click on the "Show Extended View" option at the top of the report to display the additional calculations. In cases where a question is required and only one response is allowed, all three percentages will be equal. The difference between the three calculations is most notable in a choose-all-that-apply question type that is optional.